ARS Pharmaceuticals (SPRY), Tuesday announced the submission of Day 180 response for Neffy's Marketing Authorization Application to the Committee for Medicinal Products for Human Use of the European Medicines Agency, expecting to receive the opinion on the drug in the second quarter of 2024.
Neffy or epinephrine nasal spray is an investigational drug proposed for the treatment of Type I allergic reactions including anaphylaxis.
The response covers all concerns previously raised by the Committee for Medicinal Products for Human Use (CHMP), incorporating findings from a repeat dose PK/PD study of Neffy under nasal allergen challenge (NAC) conditions and updated testing concerning nitrosamine levels.
Simultaneously, the biopharmaceutical company also signed an exclusive license and distribution agreement with CSL Seqirus, a subsidiary of CSL Ltd. to commercialize Neffy across Australia and New Zealand.
Under the agreement, ARS will receive an upfront payment as well as event-driven milestone payments.
Currently, ARS Pharma's stock is up 0.12 percent at $8.61 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.